Vertex Pharmaceuticals (VRTX, Financial) has entered into an exclusive agreement with Ono Pharmaceutical to advance the development and commercialization of its innovative treatment, povetacicept, in Japan and South Korea. Povetacicept is a promising therapeutic agent designed to combat B cell-related conditions such as immunoglobulin A nephropathy and primary membranous nephropathy.
Through this partnership, Vertex will receive an upfront payment along with regulatory and commercial milestone payments, in addition to tiered royalties. Ono will play a crucial role by leveraging its development expertise to propel Vertex's clinical trials in these regions. The company will also oversee the process of securing marketing approvals in both countries. Upon gaining approval, Ono will take charge of the commercial distribution of povetacicept in Japan and South Korea.
This collaboration not only focuses on povetacicept for immunoglobulin A nephropathy and primary membranous nephropathy but also opens the door for exploring other potential applications for the drug.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.